Aeterna Wealth

Mutual funds holding Emcure Pharmaceuticals shares

31 mutual fund schemes held Emcure Pharmaceuticals shares in their latest portfolios (October 2026, or September 2026 where a fund house's October 2026 portfolio is not yet in), worth about ₹2,174 cr in all. The largest holders by value are Kotak Mid Cap Fund (1.3% of the fund), Aditya Birla Sun Life ELSS Tax Saver Fund (1.9% of the fund), Nippon India Multi Cap Fund (0.5% of the fund).

Against the month before, 0 schemes added Emcure Pharmaceuticals as a new holding and 10 sold out of it completely.

Sold out: Samco ELSS Tax Saver Fund, Motilal Oswal BSE 1000 Index Fund, HDFC BSE 500 Index Fund, Motilal Oswal Nifty 500 Index Fund, SBI Nifty 500 Index Fund, DSP Nifty 500 Index Fund, Angel One Nifty Total Market Index Fund, Mirae Asset Nifty Total Market Index Fund, Groww Nifty Total Market Index Fund, Samco Small Cap Fund

By category: Index Fund (14), Sectoral/Thematic (7), Small Cap (3), Multi Cap (2), Flexi Cap (2), Mid Cap (1).

2 actively managed schemes holding it are rated A+ or A on their track record, among them Aditya Birla Sun Life Multi-Cap Fund, Aditya Birla Sun Life Small Cap Fund.

Every scheme holding Emcure Pharmaceuticals, by value

SchemeRating% of fundValueChange
Kotak Mid Cap FundMid CapC1.26%₹814 cr–
Aditya Birla Sun Life ELSS Tax Saver FundELSSB1.93%₹258 cr–
Nippon India Multi Cap FundMulti CapB0.46%₹241 cr-0.10
SBI Flexicap FundFlexi CapC0.98%₹212 cr-0.01
Axis Small Cap FundSmall CapB0.55%₹163 cr–
Nippon India Pharma FundSectoral/ThematicC1.32%₹120 cr-0.04
Aditya Birla Sun Life Multi-Cap FundMulti CapA1.18%₹83 cr–
Aditya Birla Sun Life Small Cap FundSmall CapA1.25%₹73 cr–
Aditya Birla Sun Life Large & Mid Cap FundLarge & Mid CapB0.96%₹52 cr–
Aditya Birla Sun Life Pharma and Healthcare FundSectoral/ThematicC3.21%₹35 cr–
Baroda BNP Paribas Small Cap FundSmall CapB2.63%₹32 cr+0.04
Bajaj Finserv Healthcare FundSectoral/Thematic–4.03%₹17 cr–
Kotak Healthcare FundSectoral/Thematic–1.77%₹15 cr–
Edelweiss Business Cycle FundSectoral/Thematic–1.06%₹14 cr–
Nippon India Nifty Smallcap 250 Index FundIndex FundB0.37%₹12 cr+0.01
Baroda BNP Paribas Health and Wellness FundSectoral/Thematic–1.57%₹8 cr-0.82
SBI Nifty Smallcap 250 Index FundIndex FundA0.37%₹6 cr+0.01
Motilal Oswal Nifty Smallcap 250 Index FundIndex FundB0.37%₹4 cr+0.01
UTI - Healthcare FundSectoral/ThematicB0.20%₹3 cr–
HDFC Nifty Smallcap 250 Index FundIndex FundB0.37%₹3 cr+0.01
ICICI Prudential Nifty Smallcap 250 Index FundIndex FundC0.36%₹3 cr–
Quantum Flexi Cap FundFlexi Cap–1.81%₹1 cr–
Edelweiss Nifty Smallcap 250 Index FundIndex FundA0.36%₹1 cr–
Nippon India Nifty 500 Equal Weight Index FundIndex FundB0.21%₹1 cr+0.01
Groww Nifty Smallcap 250 Index FundIndex FundB0.37%₹0 cr+0.01
HDFC NIFTY500 Multicap 50:25:25 Index FundIndex FundA+0.09%₹0 cr+0.00
Kotak Nifty SmallCap 250 Index FundIndex FundA0.36%₹0 cr–
UTI Nifty500 Shariah Index FundIndex Fund–0.14%₹0 cr–
DSP Nifty Smallcap 250 Index FundIndex Fund–0.37%₹0 cr+0.01
Navi Nifty 500 Multicap 50:25:25 Index FundIndex FundB0.09%₹0 cr–
Navi Nifty Midsmallcap 400 Index FundIndex Fund–0.12%₹0 cr–

Value: the scheme's assets under management × the stock's weight, approximate. Change: the weight against the previous month's portfolio, in percentage points; it moves with the share price as well as with buying and selling. Links go to each scheme's Regular plan.

Common questions

How many mutual funds hold Emcure Pharmaceuticals shares?

31 schemes held Emcure Pharmaceuticals in their latest monthly portfolios (October 2026, or September 2026 where a fund house's October 2026 portfolio is not yet in), worth about ₹2,174 cr in all.

Which mutual fund holds the most Emcure Pharmaceuticals shares?

By value, Kotak Mid Cap Fund: about ₹814 cr, 1.26% of the fund.

Where does this data come from?

From the monthly portfolios that every fund house must publish by the 10th of the following month. Values are approximate: the fund's assets under management multiplied by the stock's weight in the portfolio.

This page lists which funds hold a stock. It is not a view on the stock or a recommendation to buy or sell it or any fund. Ratings describe past track records, not a forecast.

Free portfolio review

Send us your CAS and get a written report: which of your funds to keep, which to exit and when, where new SIPs should go, and what each change costs in tax.

Chat with us